Lumateperone Added to Antidepressants Shows Sexual Function Improvement in

A newly published clinical trial indicates that augmenting standard antidepressant treatment with the second-generation antipsychotic lumateperone may yield dual benefits: alleviating depressive symptoms and improving sexual function in adults with major depressive disorder who have shown inadequate response to prior therapy.

Study design and primary outcomes

The randomized, double-blind study enrolled 480 adults diagnosed with major depressive disorder. Participants were assigned to receive either 42 mg of lumateperone once daily alongside their existing antidepressant regimen or a matching placebo. After 43 days of treatment, the lumateperone group demonstrated statistically significant improvement in both depression severity and sexual functioning relative to the placebo group.

Sexual function improvements spanned multiple domains—including desire, arousal, orgasm, and pleasure. At baseline, 82.5% of participants reported clinically significant sexual dysfunction. By the end of the treatment period, more than one-quarter of those receiving lumateperone reported restoration of sexual function to normal levels.

Gender-specific findings and limitations

Improvements were observed among both male and female participants. Female participants exhibited greater magnitude of benefit across several sexual function measures; however, researchers explicitly stated that further studies are required to confirm whether this difference is consistent and clinically meaningful. Both men and women reported enhanced sexual pleasure and arousal.

Clinical context and drug profile

The study was led by Dr. Anita H. Clayton, a psychiatrist at UVA Health, and its findings appeared in the journal Clinical Psychiatry. According to the researchers, approximately 68% of individuals with major depressive disorder experience sexual dysfunction—not solely as a consequence of depression itself, but also as a frequent adverse effect of certain antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs). This side effect may contribute to treatment discontinuation.

Lumateperone is approved for use in schizophrenia and bipolar depression, and as adjunctive therapy for major depressive disorder in adults when monotherapy with antidepressants produces insufficient improvement. The trial results suggest it may represent a viable therapeutic option for select patients with persistent depressive symptoms and concurrent sexual dysfunction. However, the authors emphasize that the data do not indicate universal efficacy across all patients, and additional research remains necessary to validate and extend these findings.